Evidence map›Paper›PMID 39004650›Full record

ReviewPurinergic signalling2025

Lessons from the physiological role of guanosine in neurodegeneration and cancer: Toward a multimodal mechanism of action?

Carla Inês Tasca, Mariachiara Zuccarini, Patrizia Di Iorio, Francisco Ciruela

Abstract readReview
In one paragraph

Review in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carla Inês TascaDepartment of Biochemistry, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, SC, Brazil. carla.tasca@ufsc.br.
Mariachiara ZuccariniDepartment of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, 66100, Chieti, Italy.
Patrizia Di IorioDepartment of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, 66100, Chieti, Italy.
Francisco CiruelaPharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 445133/2023-6Departament de Recerca i Universitats de la Generalitat de Catalunya 2021 SGR 00698Ministerio de Ciencia, Innovación y Universidades PID2020-118511RB-I00Ministero dell'Università e della Ricerca PRIN-PNRR 2022
6 · The paper itself

Abstract

Neurodegenerative diseases and brain tumours represent important health challenges due to their severe nature and debilitating consequences that require substantial medical care. Interestingly, these conditions share common physiological characteristics, namely increased glutamate, and adenosine transmission, which are often associated with cellular dysregulation and damage. Guanosine, an endogenous nucleoside, is safe and exerts neuroprotective effects in preclinical models of excitotoxicity, along with cytotoxic effects on tumour cells. However, the lack of well-defined mechanisms of action for guanosine hinders a comprehensive understanding of its physiological effects. In fact, the absence of specific receptors for guanosine impedes the development of structure-activity research programs to develop guanosine derivatives for therapeutic purposes. Alternatively, given its apparent interaction with the adenosinergic system, it is plausible that guanosine exerts its neuroprotective and anti-tumorigenic effects by modulating adenosine transmission through undisclosed mechanisms involving adenosine receptors, transporters, and purinergic metabolism. Here, several potential molecular mechanisms behind the protective actions of guanosine will be discussed. First, we explore its potential interaction with adenosine receptors (A

Indexed as

GuanosineNeoplasmsNeurodegenerative DiseasesNeuroprotective AgentsAnimalsHumansReceptors, Purinergic P1GuanosineNeuroprotective AgentsReceptors, Purinergic P1AdenosineGPCR oligomerizationGuanosineNeurodegenerationNeuroprotectionTumours

Identifiers

PMID39004650
PMCPMC11958862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.